INVA - Innoviva, Inc.
IEX Last Trade
17.515
-0.020 -0.114%
Share volume: 12,322
Last Updated: Fri 27 Dec 2024 08:30:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$17.54
-0.02
-0.11%
Fundamental analysis
48%
Profitability
70%
Dept financing
27%
Liquidity
75%
Performance
25%
Performance
5 Days
-0.79%
1 Month
-7.35%
3 Months
-8.64%
6 Months
8.95%
1 Year
8.48%
2 Year
34.02%
Key data
Stock price
$17.52
DAY RANGE
$17.42 - $17.70
52 WEEK RANGE
$14.55 - $21.28
52 WEEK CHANGE
$10.04
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: Pavel Raifeld
Region: US
Website: inva.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: inva.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
Recent news